HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer ; volume:22 ; number:1 ; day:20 ; month:10 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (20.10.2022), 1-10, 12.2022
- Creator
-
Cherifi, François
Da Silva, Angélique
Johnson, Alison
Blanc-Fournier, Cécile
Abramovici, Olivia
Broyelle, Antonin
Levy, Christelle
Allouache, Djelila
Hrab, Ioana
Segura, Carine
Morel, Adeline
Villemin, Maud
Boscher, Clémence
Dubot-Poitelon, Coraline
Rottier, Pauline
Lequesne, Justine
Emile, George
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-10163-9
- URN
-
urn:nbn:de:101:1-2023010521113952053458
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cherifi, François
- Da Silva, Angélique
- Johnson, Alison
- Blanc-Fournier, Cécile
- Abramovici, Olivia
- Broyelle, Antonin
- Levy, Christelle
- Allouache, Djelila
- Hrab, Ioana
- Segura, Carine
- Morel, Adeline
- Villemin, Maud
- Boscher, Clémence
- Dubot-Poitelon, Coraline
- Rottier, Pauline
- Lequesne, Justine
- Emile, George
- SpringerLink (Online service)
Other Objects (12)
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy